Title : Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors for cancer treatment.

Pub. Date : 2022 Mar

PMID : 34856074






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Cell lines treated with trametinib or AZD6244 in combination with AZD0424 had reduced EGFR, FAK and SRC compensatory activation, and, cell viability was synergistically inhibited. AZD 6244 epidermal growth factor receptor Mus musculus